#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Spina bifida Myelin oligodendrocyte glycoprotein antibody-associated disease B-cell small lymphocytic lymphoma recurrent Diffuse large B-cell lymphoma refractory Blastic plasmacytoid dendritic cell neoplasia Insulinoma Rhabdoid tumour Neurodevelopmental disorder Hereditary haemorrhagic telangiectasia Antiphospholipid syndrome Mucopolysaccharidosis I Small for dates baby Neuroblastoma recurrent Fragile X syndrome Angiosarcoma non-metastatic More trials…

    Learn about Rare Diseases

    Hepatic angiosarcoma – Treatment Ornithine transcarbamoylase deficiency – Life with Disease Pelizaeus-Merzbacher disease – Diagnostics Acute respiratory distress syndrome – Trials in Disease Richter’s syndrome – Life with Disease SAPHO syndrome – Trials in Disease Rett syndrome – Treatment Nephrotic syndrome Stevens-Johnson syndrome – Diagnostics Usher’s syndrome – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Trimetazidine Dihydrochloride Tertomotide Pp1815 Fluciclovine (18F) Tomligisiran Piperacillin Sodium Dornase Alfa Dexamethasone Base At-1501 LIPASE METAMIZOLE SODIUM Vanzacaftor Albiglutide Levamisole Hydrochloride Pseudoephedrine Hydrochloride Relatlimab Prucalopride Volrustomig Erythromycin Lactobionate Omalizumab More therapies…

    Learn about Your Condition

    Combined immunodeficiency Mast cell activation syndrome Elderly Triple positive breast cancer Drug eruption Schizophreniform disorder Endotracheal intubation Hysterectomy Hepatic cirrhosis Polycythaemia vera Hodgkin's disease recurrent Androgenetic alopecia Thrombocytosis Primary hyperthyroidism Small intestine adenocarcinoma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Hopitaux Universitaires Pitie Salpetriere

Hopitaux Universitaires Pitie Salpetriere

47 Boulevard De L Hopital, Paris, 75651, France

Want to learn more about this study or check if you can participate? Contact us.

  • A study comparing erdafitinib delivery system to chemotherapy for patients with high-risk non-muscle-invasive bladder cancer who received BCG treatment

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Bladder transitional cell carcinoma
    Investigated Drugs:
    • Erdafitinib
    • Mitomycin
    • Gemcitabine Hydrochloride
    Belgium France Germany Greece Italy The Netherlands +1

  • Study of KarXT (trospium chloride and xanomeline tartrate) and KarX-EC (xanomeline tartrate) for cognitive impairment in mild to moderate Alzheimer’s disease

    Recruiting

    3 1
    Investigated Diseases:
    • Dementia Alzheimer’s type
    Investigated Drugs:
    • Trospium Chloride
    • Xanomeline Tartrate
    Finland France Germany Greece Italy The Netherlands +4

  • Study of bevacizumab and trifluridine combination given bi-weekly to reduce severe neutropenia in patients with metastatic colorectal cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Colorectal adenocarcinoma
    Investigated Drugs:
    • Trifluridine
    • Bevacizumab
    France

  • Study of FOLFOX or FOLFIRI chemotherapy with fruquintinib or bevacizumab as second-line treatment for patients with metastatic colorectal cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Colorectal cancer metastatic
    Investigated Drugs:
    • FRUQUINTINIB
    • Folinic Acid
    • Bevacizumab
    France

  • Study of iodofalan (131I) and lomustine combination therapy compared to lomustine alone in patients with first recurrent glioblastoma

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Glioblastoma
    Investigated Drugs:
    • 4-IODOPHENYLALANINE I-131
    • Lomustine
    Austria Belgium Denmark France Germany The Netherlands +1

  • Study of Tarlatamab and Temozolomide combination treatment in adolescents and adults with high grade brain tumors

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Brain neoplasm
    Investigated Drugs:
    • Tarlatamab
    • Temozolomide
    France

  • Study of MP0317 with durvalumab, gemcitabine and cisplatin combination therapy as first-line treatment for patients with advanced biliary tract cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Biliary neoplasm
    Investigated Drugs:
    • Cisplatin
    • Durvalumab
    • Gemcitabine
    France

  • Study of intravenous AOC 1001 to evaluate long-term safety and effectiveness in patients with myotonic dystrophy type 1

    Recruiting

    3 1 1
    Investigated Diseases:
    • Myotonic dystrophy
    Investigated Drugs:
    • Humanised Igg1 Monoclonal Antibody Against Tfr1 Conjugated To Double Stranded Sirna Oligonucleotide Against Dmpk Via A Non-Cleavable Linker
    Denmark France Germany Italy The Netherlands Spain

  • Study of datopotamab deruxtecan with platinum-based therapy compared to gemcitabine with platinum-based therapy in patients with advanced urothelial cancer after prior treatment

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Transitional cell carcinoma
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Datopotamab Deruxtecan
    Austria Belgium Czechia Denmark France Germany +5

  • Study on the Safety and Effectiveness of Telisotuzumab Adizutecan and Drug Combination for Patients with Metastatic Colorectal Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Colorectal cancer metastatic
    Investigated Drugs:
    • Panitumumab
    • Folinic Acid
    • Bevacizumab
    Austria Czechia France Greece Italy Spain
Previous Page
1 2 3 4 … 20
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!